Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 2/20 | 0.35 |
| ▸ | JAK1 | P23458 | 2/20 | 0.35 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 11/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 11/20 | 0.34 |
| ▸ | RXRA | P19793 | 9/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | DTYMK | P23919 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | ACACA | Q13085 | 1/20 | 0.33 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5757976 | 0.90 | ALDH1A1 (0.37) | JAK2JAK1NR1H2NR1H3RXRA | |
| SCHEMBL5761497 | 0.88 | STS (0.35) | JAK2JAK1NR1H2NR1H3RXRA | |
| SCHEMBL5756285 | 0.87 | HDAC3 (0.38) | JAK2JAK1SLC9A1NR1H2NR1H3 | |
| SCHEMBL5758725 | 0.86 | SLC9A1 (0.36) | JAK2JAK1SLC9A1NR1H2NR1H3 | |
| SCHEMBL7475733 | 0.85 | BCHE (0.34) | SLC9A1CYP2C9S1PR5 | |
| SCHEMBL5755140 | 0.80 | ACACB (0.36) | JAK2JAK1NR1H2NR1H3RXRA | |
| SCHEMBL5759337 | 0.78 | L3MBTL1 (0.43) | JAK2JAK1NR1H2NR1H3RXRA | |
| SCHEMBL5758726 | 0.78 | F2RL3 (0.33) | JAK2JAK1CYP2C9NAMPTACACB | |
| SCHEMBL5760910 | 0.77 | CHRNA7 (0.36) | JAK2JAK1NR1H2NR1H3RXRA | |
| SCHEMBL5755024 | 0.77 | SLC6A2 (0.39) | JAK2JAK1NR1H2NR1H3RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7144898-B2 | Indole derivatives for the treatment of depression and anxiety | ELI LILLY AND COMPANY (US) | 2006-12-05 | — | — | US | disclosed |
| EP-1242411-B1 | INDOLE DERIVATIVES FOR THE TREATMENT OF DEPRESSION AND ANXIETY | LILLY CO ELI (US) | 2006-03-08 | — | — | EP | disclosed |
| US-20040006229-A1 | Indole derivatives for the treatment of depression and anxiety | ELI LILLY AND COMPANY | 2004-01-08 | — | — | US | disclosed |
| US-20030153764-A1 | Process for preparing 4-substituted piperidines | ELI LILLY AND COMPANY | 2003-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006229-A1 | Indole derivatives for the treatment of depression and anxiety | IDO1, TPH1, IDO2 | JAK2 558/4885JAK1 491/4885SLC9A1 2152/4885 |
| US-20030153764-A1 | Process for preparing 4-substituted piperidines | PDGFRA, GTF3C5, GRIA4 | JAK2 1413/4885JAK1 3326/4885SLC9A1 3597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.